AdAlta’s CEO and Managing Director Dr Tim Oldham held a webinar on Wednesday 3 May 2023 to discuss the recently launched A$3.15 million non-renounceable rights offer (Offer) to shareholders. During the webinar, Tim covered AdAlta’s four strategic objectives and various milestones the Company is working towards, including an early return to the clinic for AD-214.
The strategic objectives to create and crystallise value from our i-body platform include:
- Realising the value of AD-214, including the generation of new clinical data for partnering
- Extending the i-CAR programs
- Progressing i-PET development
- Investing in the i-bodyTM platform internally and through synergistic technology and product collaborations
To watch a recording of the webcast, please CLICK HERE or on the image below.
The presentation slides can also be found HERE.
AdAlta thanks investors for their ongoing interest and support. We will continue to provide updates as we reach the timetable deadlines for the Offer.